Cancer
Conditions
Keywords
Cancer, Peripheral neuropathy, Cryotherapy
Brief summary
This study aimed to assess the efficacy of cryotherapy in controlling Peripheral Neuropathy in cancer children
Detailed description
Peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. Pharmacists play a pivotal role in the prevention and management of CIPN by recommending evidence-based pharmacologic and non pharmacologic strategies appropriate for the individual patient.Peripheral neuropathy (PN) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (QOL). Prolonged symptoms associated with PN can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.
Interventions
Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
Sponsors
Study design
Masking description
Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).
Intervention model description
They were assigned randomly into two equal groups.Group (A) study group received the same medical care and cryotherapy, three times / weak for three successful months. And group (B) control group received medical care and standard chemotherapy only.
Eligibility
Inclusion criteria
1. Their age will ranging from eight to seventeen years. 2. Children participated in this study will from both sexes. 3. Children receiving chemotherapy as medical treatment protocol 4. All children have polyneuropathy caused by chemotherapy.
Exclusion criteria
1. Children with Epilepsy. 2. Children with blood clotting disorder. 3. Children have Open wounds / broken skin 4. Children with severe cardiac disease 5. Uncooperative patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nerve conduction studies (NCS) | nerve conduction velocity for sensory ulnar nerve at day 0 | nerve conduction velocity for sensory ulnar nerve |
Countries
Egypt